Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) EBT: 2020-2025

Historic EBT for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to -$16.5 million.

  • Foghorn Therapeutics' EBT rose 13.87% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.0 million, marking a year-over-year increase of 15.98%. This contributed to the annual value of -$86.6 million for FY2024, which is 8.05% up from last year.
  • Per Foghorn Therapeutics' latest filing, its EBT stood at -$16.5 million for Q3 2025, which was up 12.34% from -$18.8 million recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year EBT high stood at -$13.6 million for Q3 2023, and its period low was -$29.9 million during Q1 2023.
  • Moreover, its 3-year median value for EBT was -$20.2 million (2025), whereas its average is -$21.5 million.
  • Per our database at Business Quant, Foghorn Therapeutics' EBT slumped by 68.90% in 2021 and then spiked by 47.20% in 2023.
  • Over the past 5 years, Foghorn Therapeutics' EBT (Quarterly) stood at -$28.5 million in 2021, then declined by 1.33% to -$28.9 million in 2022, then grew by 23.42% to -$22.1 million in 2023, then grew by 11.83% to -$19.5 million in 2024, then grew by 13.87% to -$16.5 million in 2025.
  • Its EBT was -$16.5 million in Q3 2025, compared to -$18.8 million in Q2 2025 and -$20.2 million in Q1 2025.